Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 Monotherapy or with Nab-paclitaxel in TNBC
NCT03872791Phase 2Completed
- Sponsor
- Alphamab Oncology
- Start
- May 2019
- Primary completion
- Aug 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of erfonrilimab in triple-negative breast cancer (TNBC), sponsored by Alphamab Oncology. Started May 2019; status: completed.
02
Drugs
erfonrilimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03872791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03872791.